Join our project
The development of an effective vaccine against SARS-CoV-2 represents the only hope of preventing further epidemics and outbreaks of the disease.
The Quilmes Clinical Research Institute was chosen by the prestigious German company CureVac AG to carry out this project: a Phase 2b / 3 clinical research study, which compares two doses of vaccine vs. Placebo, the only way to demonstrate efficacy and safety. This study is carried out in more than 30,000 volunteers, over 18, in Germany, Belgium, the Netherlands, the Dominican Republic, Colombia, Panama, Peru, Mexico, Spain and Argentina.
IF YOU ARE INTERESTED IN PARTICIPATING IN THIS RESEARCH STUDY, PLEASE READ THE INCLUSION AND EXCLUSION CRITERIA BELOW TO SEE IF YOU CAN PARTICIPATE.
Inclusion criteria
The inclusion criteria for all volunteers are those conditions they must have in order to participate
Male or female subjects 18 years of age or older.
. Compliance with the protocol procedures is expected and that they are available for clinical follow-up until the last planned visit.
Women of childbearing age: negative result in the urine pregnancy test (human chorionic gonadotropin, hCG) performed at the Institute at the time of admission.
Women of childbearing potential should use highly effective contraception from 2 weeks before the first vaccine administration to 3 months after the last administration. The use of any investigational or unregistered product (vaccine or drug) within 28 days prior to the administration of the first trial vaccine or planned use during the trial. Have received authorized vaccinations within 28 days (for live vaccines) or 14 days (for inactivated vaccines) before the administration of the first test vaccine. Previous administration of any investigational or other SARS-CoV-2 vaccine. Subjects with a significant acute or chronic medical or psychiatric illness
Exclusion criteria
The exclusion criteria for all volunteers: are those that you must not present in order to participate
History of swab-confirmed COVID-19 illness.
For women: pregnancy or lactation.
Treatment with immunomodifying drugs (corticosteroids, biological agents and methotrexate among others) for a total of> 14 days within the previous 6 months.
Known infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus; current diagnosis or treatment for cancer.
History of angioedema (hereditary or idiopathic) or history of any anaphylactic reaction or severe allergies.
History of allergy to any component of the vaccine.
Administration of immunoglobulins or any blood derivatives within 3 months prior to the administration of the trial vaccine or administration planned during the trial.
The use of any investigational or unregistered product (vaccine or drug) within 28 days prior to the administration of the first trial vaccine or planned use during the trial.
Have received authorized vaccinations within 28 days (for live vaccines) or 14 days (for
inactivated vaccines) prior to administration of the first test vaccine.Previous administration of any investigational or other SARS-CoV-2 vaccine
Subjects with a significant acute or chronic medical or psychiatric illness
If you meet the inclusion criteria:
It does not present any exclusion criteria and you want to participate as a volunteer in this vaccine research protocol for COVID 19, or if you have any questions, complete the following personal information so we will contact you by phone, email or WhatsApp.
Registration form - Volunteering COVID 19
Please fill in the details, they are all required. We will contact you shortly to schedule an attention shift.
IMPORTANT: You must go to the center with an Identity Document and accompanied by a person of legal age, ideally, friend, neighbor, etc., strictly complying with the schedule. Remember that crowding of people will be avoided, and the rules of care will be met to avoid contagion of COVID 19, having to enter with a properly placed mask.
About Covid 19
Coronaviruses are a family of viruses with an RNA genome, which cause respiratory diseases, which can range from the common cold to serious illnesses. In December 2019, an outbreak of a respiratory illness caused by a new strain of the coronavirus was reported in the city of Wuhan, China. The new coronavirus was called "severe acute respiratory syndrome coronavirus type 2" (SARS-CoV-2), while the disease associated with it was called COVID-19. On March 12, 2020, the WHO announced the outbreak as a pandemic.
The development of an effective vaccine against SARS-CoV-2 represents the only hope of preventing further epidemics and outbreaks of the disease.
CureVac AG, a German biotech company that studies RNA for many years is developing a new vaccine against SARS-CoV-2 called CVnCoV based on mRNA. After intramuscular injection of CVnCoV, a cellular and humoral immune response is stimulated that would prevent contagion or cause the disease to have a more benign course.
That is why the world began with a Phase 2b / 3 clinical research study, which compares two doses of vaccine vs. Placebo, the only way to demonstrate efficacy and safety, multicenter in countries such as Germany, Belgium, the Netherlands, the Dominican Republic, Colombia, Panama, Peru, Mexico, Spain and Argentina. among others, in more than 30,000 volunteers over 18 years of age and with a duration of a little more than 1 year.
Recently, the Bayer laboratory, one of the largest pharmaceutical companies in the world, joined this project, which gives very important support to the development of the vaccine and will provide access to international pharmaceutical markets, as well as to its global supply chain. and distribution network (greater access to the world population)
